Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
W Ray KimLaura E TelepBelinda JumpMei LuHeribert RamrothJohn FlahertyAnuj GaggarAnand P ChokkalingamStuart C GordonPublished in: Alimentary pharmacology & therapeutics (2022)
Among commercially insured, treatment-naïve patients with chronic hepatitis B in the United States, treatment with TDF was associated with significantly lower risk of HCC than ETV.